Last reviewed · How we verify
Postbiotic
At a glance
| Generic name | Postbiotic |
|---|---|
| Sponsor | Liverpool John Moores University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents (NA)
- Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS (NA)
- Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) (PHASE2)
- Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels (NA)
- Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms (NA)
- Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults (NA)
- The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers (NA)
- Impact of a Novel Brain Longevity Supplement Containing the Postbiotic Urolithin A (Mitopure) on Cognitive Function and Related Health Outcomes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Postbiotic CI brief — competitive landscape report
- Postbiotic updates RSS · CI watch RSS
- Liverpool John Moores University portfolio CI